Some recent analyst ratings include

• 11/8/2019-
  Adamas Pharmaceuticals Inc (NASDAQ:ADMS) had its Hold rating reiterated by Needham & Company LLC
• 11/8/2019-
  Adamas Pharmaceuticals Inc (NASDAQ:ADMS) had its Buy rating reiterated by Northland Securities with a $15.00 price target
• 9/30/2019-
  Adamas Pharmaceuticals Inc (NASDAQ:ADMS) gets downgraded to Underperform by Bank of America with a price target of $5.00
• 9/9/2019-
  Adamas Pharmaceuticals Inc (NASDAQ:ADMS) has coverage initiated with a Neutral rating and $8.00 price target
• 8/12/2019-
  Adamas Pharmaceuticals Inc (NASDAQ:ADMS) had its Buy rating reiterated by Evercore ISI with a $55.00 price target

• On 9/20/2019 Alfred G Merriweather, CFO, sold 1,584 with an average share price of $6.91 per share and the total transaction amounting to $10,945.44.
• On 7/22/2019 Christopher B Prentiss, Insider, sold 1,082 with an average share price of $6.00 per share and the total transaction amounting to $6,492.00.
• On 6/20/2019 Jennifer J. Rhodes, Insider, sold 940 with an average share price of $5.35 per share and the total transaction amounting to $5,029.00.
• On 3/20/2019 Alfred G Merriweather, CFO, sold 857 with an average share price of $7.99 per share and the total transaction amounting to $6,847.43.
• On 3/20/2019 Christopher B Prentiss, Insider, sold 1,185 with an average share price of $8.00 per share and the total transaction amounting to $9,480.00.
• On 3/20/2019 Gregory T Went, CEO, sold 6,319 with an average share price of $7.99 per share and the total transaction amounting to $50,488.81.
• On 12/20/2018 Christopher B. Prentiss, CAO, sold 228 with an average share price of $7.51 per share and the total transaction amounting to $1,712.28.

Recent Trading Activity for